与依法韦仑相比，多替拉韦对HIV感染者体重变化和血脂谱的影响：一项回顾性队列研究。

Effect of dolutegravir on weight changes and lipid profile compared with efavirenz in people living with HIV: A retrospective cohort study.

作者信息

Setpakdee Rachawit, Kiertiburanakul Sasisopin

机构信息

Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Bangkok 10400, Thailand.

出版信息

J Infect Public Health. 2025 Feb;18(2):102630. doi: 10.1016/j.jiph.2024.102630. Epub 2024 Dec 26.

DOI:10.1016/j.jiph.2024.102630

PMID:39778463

Abstract

BACKGROUND

There are limited data on DTG-associated weight gain among treatment-naïve Asian people living with HIV (PLHIV).

METHODS

Eighty-one and 100 PLHIV initiating DTG-based and efavirenz (EFV)-based antiretroviral therapy (ART), respectively, were retrospectively investigated for weight changes and lipid profiles at 6 and 12 months after ART initiation.

RESULTS

At baseline, the DTG group had a lower mean body weight (BW) (60.7 kg vs. 64.3 kg, p = 0.071) and lower mean cholesterol level (172 mg/dL vs. 185 mg/dL, p = 0.029) than the EFV group. Mean BW remained lower in the DTG group than in the EFV group at 6 [58.2 kg vs. 66.0 kg, mean difference (MD) -7.8, p = 0.005] and 12 (59.6 kg vs. 67.0 kg, MD -7.3, p = 0.008) months. BW did not significantly change between baseline and 12 months in the DTG group (60.7 kg vs. 59.6 kg, p = 0.495), whereas it significantly increased between baseline and 12 months in the EFV group (64.3 kg vs. 66.9 kg, p = 0.019). Cholesterol levels did not significantly increase between baseline and 12 months in either group. After adjustment, DTG use [MD -5.85, 95 % confidence interval (CI) -10.45, -1.24, p = 0.013] and baseline BW (MD 0.97, 95 % CI 0.79, 1.15, p < 0.001) were significantly associated with BW changes over time.

CONCLUSIONS

DTG-based ART was not significantly associated with increased BW and cholesterol levels compared with EFV-based ART in treatment-naïve Thai PLHIV.

摘要

背景

在未接受过治疗的亚洲艾滋病病毒感染者（PLHIV）中，关于多替拉韦（DTG）相关体重增加的数据有限。

方法

分别对81例和100例开始接受基于DTG和基于依非韦伦（EFV）的抗逆转录病毒疗法（ART）的PLHIV进行回顾性研究，观察ART开始后6个月和12个月时的体重变化和血脂情况。

结果

基线时，DTG组的平均体重（BW）低于EFV组（60.7千克对64.3千克，p = 0.071），平均胆固醇水平也低于EFV组（172毫克/分升对185毫克/分升，p = 0.029）。在6个月时（58.2千克对66.0千克，平均差值（MD）-7.8，p = 0.005）和12个月时（59.6千克对67.0千克，MD -7.3，p = 0.008），DTG组的平均BW仍低于EFV组。DTG组基线至12个月时BW无显著变化（60.7千克对59.6千克，p = 0.495），而EFV组基线至12个月时BW显著增加（64.3千克对66.9千克，p = 0.019）。两组基线至12个月时胆固醇水平均无显著升高。调整后，使用DTG（MD -5.85，95%置信区间（CI）-10.45，-1.24，p = 0.013）和基线BW（MD 0.97，95% CI 0.79，1.15，p < 0.001）与随时间的BW变化显著相关。